Watt, April C. http://orcid.org/0000-0002-5145-5334
Cejas, Paloma
DeCristo, Molly J.
Metzger-Filho, Otto
Lam, Enid Y. N. http://orcid.org/0000-0001-5843-7836
Qiu, Xintao http://orcid.org/0000-0002-8560-7017
BrinJones, Haley
Kesten, Nikolas http://orcid.org/0000-0002-9183-8778
Coulson, Rhiannon
Font-Tello, Alba
Lim, Klothilda
Vadhi, Raga
Daniels, Veerle W.
Montero, Joan http://orcid.org/0000-0002-9192-4836
Taing, Len
Meyer, Clifford A.
Gilan, Omer
Bell, Charles C. http://orcid.org/0000-0003-2194-8311
Korthauer, Keegan D.
Giambartolomei, Claudia http://orcid.org/0000-0003-2786-1225
Pasaniuc, Bogdan
Seo, Ji-Heui
Freedman, Matthew L. http://orcid.org/0000-0002-0151-1238
Ma, Cynthia http://orcid.org/0000-0002-8156-7492
Ellis, Matthew J.
Krop, Ian
Winer, Eric
Letai, Anthony http://orcid.org/0000-0002-1993-9013
Brown, Myles
Dawson, Mark A. http://orcid.org/0000-0002-5464-5029
Long, Henry W. http://orcid.org/0000-0001-6849-6629
Zhao, Jean J. http://orcid.org/0000-0002-4561-5688
Goel, Shom http://orcid.org/0000-0001-8329-9084
Article History
Received: 26 June 2020
Accepted: 29 September 2020
First Online: 9 November 2020
Competing interests
: S.G. is the recipient of research funding from Eli Lilly and Co., which has been used to support a part of this work. S.G. has served as a paid advisory board member for Eli Lilly and Co., G1 Therapeutics, Pfizer and Novartis. S.G. also conducts laboratory research sponsored by G1 Therapeutics and clinical research sponsored by Eli Lilly and Co. and by Novartis. J.J.Z. is founder and board director of Crimson Biotech and Geode Therapeutics. J.M. is a consultant for Oncoheroes Biosciences and Vivid Biosciences. M.B. receives sponsored research support from Novartis. M.B. is a consultant to H3 Biomedicine and serves on the SAB of Kronos Bio and GV20 Therapeutics. C.M. is a consultant for Pfizer, Novartis, Seattle Genetics and Eli Lilly and Co. and receives institutional research funding from Pfizer and Puma. I.K. receives institutional research funding and grants from Genentech/Roche and Pfizer. I.K. is an advisory board participant, consultant and has received honoraria from Daiichi/Sankyo, Macrogenics and Genentech/Roche. I.K. is an advisory board participant and has received honoraria from Context Therapeutics, Taiho Oncology and Seattle Genetics. I.K. is a data monitoring board member at Novartis. E.W. is a consultant at and has received honoraria from Carrick Therapeutics, DragonFly, Genentech/Roche, Genomic Health, GSK, Jounce, Eli Lilly and Co., Seattle Genetics and Merck. E.W. is a scientific advisory board member and has received honoraria from Leap. M.E. has patents and receives royalties from prosigna/Nanostring. O.M.-F. receives institutional research funding from AbbVie, Genentech, Roche and Pfizer, and has received honoraria from Roche. M.A.D. has been a member of the advisory boards for CTX CRC, Storm Therapeutics, Celgene and Cambridge Epigenetix. The Dawson laboratory receives research funding from CTX CRC. All other authors declare no competing interests.